NSCLC metastatic/no molecular target

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 19/01/2023)

1st line
ImmunoSABR (Academic)
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.

PDC-LUNG-101 (PDC*line)
Safety, Immunogenicity and Preliminary Clinical Activity Study of  PDC*Lung01 Cancer Vaccine in NSCLC.
(cohort B2 open)

2nd line 
CARMEN-LC03 (Sanofi) (after chemo- and immunotherapy)
SAR408701 (tusamitamab ravtansine; ADC) Versus Docetaxel in Previously Treated CEACAM5 Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients.

CARMEN-LC06 (Sanofi) (after chemo- and immunotherapy)
Open label, Phase 2 study, evaluating the efficacy and safety of tusamitamab ravtansine (ADC) in participants with CEACAM5 negative-moderate expression and high circulating CEA non-squamous non-small-cell lung cancer (NSQ NSCLC).

ImmunoSABR (Academic)
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.

Aurelio-04 (Sotio) (after chemo- and/or immunotherapy)

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors. 

3rd line
ImmunoSABR (Academic) 
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.